Skip to main content
ATOS logo

ATOS · Atossa Therapeutics, Inc. · Documents

Track ATOS — free
$1.65 -0.10 (-5.71%) Q2 2023 earnings call transcript
Market Cap
$15.92M
Shares
9.98M
Volume · Nov 20 48.93K Avg daily vol (3M) 67.59K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $34.77M 10-K filed Mar 25, 2026 Quarterly report FY2026 Q3 Net loss $5.64M 10-Q filed Nov 10, 2026 Latest results CVR shares 25% of voucher proceeds capped at $50 million 8-K filed Nov 10, 2026 Earnings call Q2 2023 earnings call Held Aug 14, 2023
2026
Nov 10
Current report 8-K
CVR shares 25% of voucher proceeds capped at $50 million

Atossa Therapeutics, Inc. said CVR holders are entitled to 25% of net proceeds from monetizing its first priority review voucher, capped at $50 million. Third-quarter operating expenses were $5.9 million, down from $9.3 million.

Financial results
3 source passages
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent corporate developments. CVR holders will be entitled, in the aggregate, to 25% of the net proceeds from the sale or other monetization of the first qualifying U.S. Food and Drug Administration (FDA) priority review voucher (PRV) awarded to Atossa, subject to a maximum aggregate payment of $50 million. Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Z-Endoxifen advances in four Phase 2 trials

Atossa Therapeutics said (Z)-endoxifen is being investigated in four Phase 2 trials. Nine-month 2026 operating expenses were $24.5 million, down from $25.7 million, and net cash used in operating activities was (24,745) thousand.

Net loss $5.64M Diluted EPS -$0.56
Read from the MD&A section
3 source passages
(Z)-Endoxifen is currently being investigated in four Phase 2 trials, including the completed Karisma trial: Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, respectively, which represented a decrease of $3.4 million and $1.2 million from total operating expenses for the three and nine months ended September 30, 2025, which were $9.3 million and $25.7 million, respectively. Net cash used in operating activities | (24,745) | (19,223) Open the document at this passage
Oct 9
Current report 8-K Events of Oct 8
Entered into a material agreement, Change to shareholders' rights, Other events

Atossa Therapeutics declared one stapled contingent value right per common share, payable from 25% of net proceeds of the first FDA priority review voucher awarded by December 31, 2036, up to $50 million. No voucher has been awarded.

Read from the first part of this long document
Sep 29
Current report 8-K
Other events

Atossa Therapeutics approved a plan to issue one contingent value right per common share, entitling holders to 25% of net proceeds from monetizing its first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.

Apr 16
Current report 8-K Events of Apr 13
Other events AI summary on its way
Mar 25
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $34.77M Diluted EPS -$4.04
Jan 6
Current report 8-K
Other events AI summary on its way
2025
2024
Showing 1–50 of 148 documents
Key facts CIK 1488039 CUSIP 04962H704 13F (30d) 61 filings 35 filers Visit website Investor relations